Market Overview

UPDATE: Allergan Upgraded by Citigroup on Strong Fundamentals

Share:
Related AGN
Teva Pharmaceuticals Has Had An Eventful 24 Hours
Key Exec Announcing His Retirement From Teva 'Creates More Uncertainties'
PRO Weekly Digest: Revisiting Healthcare Ideas, Plus Some Of Our Top Articles This Week (Seeking Alpha)

Tuesday morning rating updates include an upgrade from Citigroup analyst Liav Abraham, boosting Allergen (NYSE: AGN) from Neutral to Buy, with a price rating of $130 from $95.

Citigroup is sold on Allergan's long-term growth with strong balance sheet and cash flow to back up their rating change. The report notes, "Following the recent removal of the Restasis and Lumigan overhangs, the fundamental risk-reward profile of AGN has shifted, in our view, with the stock offering the most attractive organic growth profile amongst the peer group, along with significant balance sheet optionality."

AGN is currently trading up around the $114 mark after closing Monday at $112.26.

Latest Ratings for AGN

DateFirmActionFromTo
Nov 2016Morgan StanleyMaintainsOverweight
Oct 2016BarclaysAssumesEqual-Weight
Aug 2016MizuhoUpgradesNeutralBuy

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Citigroup Liav AbrahamUpgrades Price Target Analyst Ratings

 

Related Articles (AGN)

View Comments and Join the Discussion!